Studies of a Ras Antagonist in Breast Cancer

Abstract

The aim of this project is preclinical testing of a novel Ras antagonist, farnesylthiosalicylate (FTS in complex with a cyclodextrin (CD) carrier. Ras is involved in estrogen and growth factor signaling in breast cancer cells. inhibition of Ras should prevent growth of breast cancer cells. We have tested FTS-CD against several breast cancer cell lines in vitro and found that: * FTS-CD is effective against estrogen receptor positive breast cancer in vitro. * FTS-CD is effective against Tamoxifen resistant cells in vitro. * FTS-CD interferes with estrogen signaling. * FTS-CD induces profound changes in cell signaling, manifested as increase in apoptosis and decrease in proliferation.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2003
Accession Number
ADA416652

Entities

People

  • Robert A. McPherson

Organizations

  • University of Virginia

Tags

DTIC Thesaurus Topics

  • Alkenes
  • Apoptosis
  • Biomedical Research
  • Breast Cancer
  • Cell Line
  • Cell Membrane
  • Cell Physiological Processes
  • Cells
  • Cellular Structures
  • Estrogens
  • Growth Factors
  • Indicator Dyes
  • Neoplasms
  • Proteins
  • Resistance
  • Therapy
  • Tumor Cell Line

Fields of Study

  • Biology

Readers

  • Breast cancer cell signaling and growth regulation.